Selected research
Market Structure
Global mRNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global mRNA Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for mRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for mRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for mRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for mRNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of mRNA Drug include Janssen, Sri Lankan Microorganisms, Pfizer, Fosun Pharma, AstraZeneca, Zydus Cadila, Moderna, CureVAC and BioNtech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global mRNA Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of mRNA Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents mRNA Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the mRNA Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
mRNA Drug Segment by Company
Janssen
Sri Lankan Microorganisms
Pfizer
Fosun Pharma
AstraZeneca
Zydus Cadila
Moderna
CureVAC
BioNtech
mRNA Drug Segment by Type
Therapeutic Vaccine
Therapeutic Drugs
Preventive Vaccines
mRNA Drug Segment by Application
Hospital
Clinic
mRNA Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the mRNA Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of mRNA Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of mRNA Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of mRNA Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Therapeutic Vaccine
- Therapeutic Drugs
- Preventive Vaccines
Applications
- Hospital
- Clinic
Companies covered
- Janssen
- Sri Lankan Microorganisms
- Pfizer
- Fosun Pharma
- AstraZeneca
- Zydus Cadila
- Moderna
- CureVAC
- BioNtech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global mRNA Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global mRNA Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global mRNA Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global mRNA Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global mRNA Drug Market Dynamics
- 2.1 mRNA Drug Industry Trends
- 2.2 mRNA Drug Industry Drivers
- 2.3 mRNA Drug Industry Opportunities and Challenges
- 2.4 mRNA Drug Industry Restraints
3 mRNA Drug Market by Manufacturers
- 3.1 Global mRNA Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global mRNA Drug Sales by Manufacturers (2021-2026)
- 3.3 Global mRNA Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global mRNA Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global mRNA Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global mRNA Drug Manufacturers, Product Type & Application
- 3.7 Global mRNA Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global mRNA Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 mRNA Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 mRNA Drug Tier 1, Tier 2, and Tier 3
4 mRNA Drug Market by Type
- 4.1 mRNA Drug Type Introduction
- 4.1.1 Therapeutic Vaccine
- 4.1.2 Therapeutic Drugs
- 4.1.3 Preventive Vaccines
- 4.2 Global mRNA Drug Sales by Type
- 4.2.1 Global mRNA Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global mRNA Drug Sales by Type (2021-2032)
- 4.2.3 Global mRNA Drug Sales Market Share by Type (2021-2032)
- 4.3 Global mRNA Drug Revenue by Type
- 4.3.1 Global mRNA Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global mRNA Drug Revenue by Type (2021-2032)
- 4.3.3 Global mRNA Drug Revenue Market Share by Type (2021-2032)
5 mRNA Drug Market by Application
- 5.1 mRNA Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global mRNA Drug Sales by Application
- 5.2.1 Global mRNA Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global mRNA Drug Sales by Application (2021-2032)
- 5.2.3 Global mRNA Drug Sales Market Share by Application (2021-2032)
- 5.3 Global mRNA Drug Revenue by Application
- 5.3.1 Global mRNA Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global mRNA Drug Revenue by Application (2021-2032)
- 5.3.3 Global mRNA Drug Revenue Market Share by Application (2021-2032)
6 Global mRNA Drug Sales by Region
- 6.1 Global mRNA Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global mRNA Drug Sales by Region (2021-2032)
- 6.2.1 Global mRNA Drug Sales by Region (2021-2026)
- 6.2.2 Global mRNA Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America mRNA Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America mRNA Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe mRNA Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe mRNA Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific mRNA Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific mRNA Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa mRNA Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa mRNA Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global mRNA Drug Revenue by Region
- 7.1 Global mRNA Drug Revenue by Region
- 7.1.1 Global mRNA Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global mRNA Drug Revenue by Region (2021-2026)
- 7.1.3 Global mRNA Drug Revenue by Region (2027-2032)
- 7.1.4 Global mRNA Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America mRNA Drug Revenue (2021-2032)
- 7.2.2 North America mRNA Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe mRNA Drug Revenue (2021-2032)
- 7.3.2 Europe mRNA Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific mRNA Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific mRNA Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa mRNA Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa mRNA Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Janssen
- 8.1.1 Janssen Company Information
- 8.1.2 Janssen Business Overview
- 8.1.3 Janssen mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Janssen mRNA Drug Product Portfolio
- 8.1.5 Janssen Recent Developments
- 8.2 Sri Lankan Microorganisms
- 8.2.1 Sri Lankan Microorganisms Company Information
- 8.2.2 Sri Lankan Microorganisms Business Overview
- 8.2.3 Sri Lankan Microorganisms mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sri Lankan Microorganisms mRNA Drug Product Portfolio
- 8.2.5 Sri Lankan Microorganisms Recent Developments
- 8.3 Pfizer
- 8.3.1 Pfizer Company Information
- 8.3.2 Pfizer Business Overview
- 8.3.3 Pfizer mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pfizer mRNA Drug Product Portfolio
- 8.3.5 Pfizer Recent Developments
- 8.4 Fosun Pharma
- 8.4.1 Fosun Pharma Company Information
- 8.4.2 Fosun Pharma Business Overview
- 8.4.3 Fosun Pharma mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Fosun Pharma mRNA Drug Product Portfolio
- 8.4.5 Fosun Pharma Recent Developments
- 8.5 AstraZeneca
- 8.5.1 AstraZeneca Company Information
- 8.5.2 AstraZeneca Business Overview
- 8.5.3 AstraZeneca mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 AstraZeneca mRNA Drug Product Portfolio
- 8.5.5 AstraZeneca Recent Developments
- 8.6 Zydus Cadila
- 8.6.1 Zydus Cadila Company Information
- 8.6.2 Zydus Cadila Business Overview
- 8.6.3 Zydus Cadila mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Zydus Cadila mRNA Drug Product Portfolio
- 8.6.5 Zydus Cadila Recent Developments
- 8.7 Moderna
- 8.7.1 Moderna Company Information
- 8.7.2 Moderna Business Overview
- 8.7.3 Moderna mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Moderna mRNA Drug Product Portfolio
- 8.7.5 Moderna Recent Developments
- 8.8 CureVAC
- 8.8.1 CureVAC Company Information
- 8.8.2 CureVAC Business Overview
- 8.8.3 CureVAC mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 CureVAC mRNA Drug Product Portfolio
- 8.8.5 CureVAC Recent Developments
- 8.9 BioNtech
- 8.9.1 BioNtech Company Information
- 8.9.2 BioNtech Business Overview
- 8.9.3 BioNtech mRNA Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 BioNtech mRNA Drug Product Portfolio
- 8.9.5 BioNtech Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 mRNA Drug Value Chain Analysis
- 9.1.1 mRNA Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 mRNA Drug Production Mode & Process
- 9.2 mRNA Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 mRNA Drug Distributors
- 9.2.3 mRNA Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst